WELCOME TO

Pronidesivir Tablets Official Site

MiaiteNeoFipronis

Pronidesivir Tablets Official Site

MiaiteNeoFipronis

Pronidesivir Tablets Oral Formulation & Drug Information

NeoFipronis® (Pronidesivir) is the first officially approved oral FIP treatment available through regulated veterinary channels. It sets a new standard in FIP care with proven clinical efficacy, safety, and global accessibility.

Official Oral FIP Treatment - No injections, less pain for cats.

Fast Absorption - High bioavailability for quick, effective results.

Proven by Research - Improves recovery and survival rates.

Treats All Types - Works for wet, dry, neuro, and eye FIP.

Vet Recommended - Trusted by vets, loved by pet parents.

Easy to Use at Home - Tablets make daily dosing simple.

Worldwide Access - Available globally for more cats in need.

NEW Breakthrough in Feline Health!

We’re proud to introduce NeoFipronis® (Pronidesivir) — the world’s first officially approved oral treatment for FIP in cats. In partnership with leading veterinary researchers, we’re bringing life-saving innovation to felines worldwide.

Who We Serve

Mother and child illustration

Pet Owners

We provide trusted, science-backed FIP treatment to give your cat the chance it deserves—because every purr matters.

School-age girl

Veterinary Clinics

Partnering with licensed clinics to deliver compliant, effective care for cats diagnosed with FIP.

Elderly couple

Global Distributors

We welcome global partners to join us in making NeoFipronis® accessible to cats in need around the world.

NeoFipronis® (Pronidesivir Tablets)


Effective for all forms of feline infectious peritonitis (FIP): effusive, non-effusive, neurological, and ocular.

  • Dosage

    15mg/kg once daily (half a 30mg tablet per kg); increase for neuro/ocular FIP as advised by a vet.

  • Administration Time

    Give once daily on an empty stomach, at the same time each day.

  • Treatment Duration

    At least 12 weeks; extend for severe cases. Continue 2 weeks after recovery and observe 8 weeks post-treatment.

  • Precautions

    Avoid missed or changed doses. Watch appetite, energy, temperature. Do regular blood tests, ensure good nutrition, and reduce stress.

NeoFipronis® (Pronidesivir) is the world’s first officially approved oral treatment for feline infectious peritonitis (FIP), offering a safe, effective, and non-invasive solution. Its high oral bioavailability ensures fast absorption and strong efficacy. The tablet form avoids the pain and stress of injections, making it easier for both cats and owners. Suitable for all types of FIP—effusive, non-effusive, neurological, and ocular—it helps relieve symptoms and improve survival rates. With clear dosing, once-daily administration, and strong clinical support, NeoFipronis® (Pronidesivir) is trusted by veterinarians and cat parents worldwide as a reliable option for at-home treatment.

The Treatment You Trust. The Quality Your Cat Deserves.

With NeoFipronis® (Pronidesivir), you’re choosing a scientifically proven FIP treatment backed by veterinary expertise and strict quality control. Every tablet reflects our commitment to safety, consistency, and care.

In a field where accuracy can mean life or death, NeoFipronis® (Pronidesivir) raises the standard. From formulation to packaging, we follow rigorous protocols to ensure every dose delivers what your cat needs — no compromises, no shortcuts.

Why Pronidesivir Tablets ?

  • First officially approved oral treatment for FIP
  • Manufactured under strict veterinary standards
  • Trusted by vets, backed by science
  • Accurate dosage, easy and safe to administer
  • Multiple quality checks for consistent efficacy
  • Globally compliant and internationally available

NeoFipronis® (Pronidesivir) — your trusted solution for FIP treatment.

Articles & News

NeoFipronis® (Pronidesivir) Officially Launched as an Oral GS-441524 Tablet for FIP Treatment
Containing GS-441524, NeoFipronis® (Pronidesivir) provides convenient oral administration, batch traceability, and quality-control support for cats with feline infectious peritonitis.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.NeoFipronis® (Pronidesivir) has been officially registered in Laos and is now available through authorized channels. The launch marks an important step toward providing a more standardized, traceable, and quality-controlled oral GS-441524 veterinary product for FIP treatment.During FIP treatment, long-term, regular, and consistent medication management is essential. Traditional injectable options may cause pain, stress, and handling challenges for cats, while also increasing the difficulty of daily administration for cat owners. NeoFipronis® (Pronidesivir) is formulated as an oral tablet to help improve dosing convenience during long-term treatment.NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is its active ingredient. The product is manufactured under controlled quality standards and supports batch traceability and product verification, helping reduce quality and safety risks associated with non-standard or unauthorized products.NeoFipronis® (Pronidesivir) focuses not only on the product itself, but also on information transparency and standardized use throughout the FIP treatment process. Pronidesivir.com, the official website of NeoFipronis® (Pronidesivir), will continue to provide product information, frequently asked questions, usage guidance, batch inquiry, and authorized-channel information to help cat owners better understand the product.The launch of NeoFipronis® (Pronidesivir) represents an important step in promoting the standardization of FIP treatment products. The brand will continue to build long-term support around product quality, veterinary guidance, reliable information, and user assistance.
NeoFipronis® (Pronidesivir) Officially Introduced, Focusing on Feline Infectious Peritonitis Treatment
As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is committed to providing a more convenient, transparent, and traceable oral GS-441524 product option for cats with FIP.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has been officially introduced as an oral GS-441524 veterinary product focused on feline infectious peritonitis (FIP).NeoFipronis® (Pronidesivir) has been officially registered in Laos and is available through authorized channels. The product is designed to support a more standardized, traceable, and quality-controlled oral veterinary product option for FIP-related treatment management.NeoFipronis® is the brand name of Pronidesivir. The product uses GS-441524 as its active ingredient and is formulated as oral tablets, aiming to meet the medication needs of cats with FIP during long-term treatment under veterinary guidance.Feline infectious peritonitis is a serious disease associated with mutations of feline coronavirus. It may present with clinical signs such as abdominal effusion, pleural effusion, persistent fever, loss of appetite, weight loss, ocular symptoms, or neurological symptoms. Diagnosis and treatment of FIP require consideration of clinical signs, laboratory testing, imaging findings, and professional veterinary judgment.The introduction of NeoFipronis® (Pronidesivir) focuses on addressing several key concerns commonly raised by cat owners regarding FIP-related products: whether the product source is legitimate, whether the ingredients are clearly defined, whether each batch is traceable, whether quality is controlled, and whether the medication is convenient for long-term administration.NeoFipronis® will continue to improve its product trust system around “official registration, legitimate source, batch traceability, and quality control.” The website will provide product information, instructions for use, authorized-channel information, and verification support to help cat owners and veterinarians better understand the product.
NeoFipronis® (Pronidesivir) Completes Official Registration in Laos, Advancing the Standardization of FIP Treatment Products
Containing GS-441524 in an oral tablet form, NeoFipronis® (Pronidesivir) provides a quality-controlled and traceable veterinary product option for feline infectious peritonitis (FIP)-related treatment management.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has completed official registration in Laos and is now available through authorized channels as an oral GS-441524 veterinary tablet.This official registration represents an important milestone in the development of NeoFipronis® (Pronidesivir), reflecting continued commitment to product standardization, quality control, and batch traceability.NeoFipronis® is the brand name of Pronidesivir. As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is designed to support cats with feline infectious peritonitis (FIP) under veterinary guidance, while helping veterinarians and cat owners access a clearer and more verifiable product source.For many years, FIP-related treatment products have faced challenges such as unclear product sources, inconsistent quality standards, and limited dosage transparency. Through official registration, batch traceability, and authorized-channel supply, NeoFipronis® (Pronidesivir) aims to reduce the potential risks associated with non-standard or unauthorized products.The product is formulated as oral tablets and may be used under veterinary guidance according to the cat’s body weight, clinical type, and changes in condition. Compared with injectable formulations, oral tablets may help improve dosing convenience during long-term treatment and reduce daily administration stress for cats.NeoFipronis® will continue to improve its product quality system, batch verification mechanism, and professional information support to provide more reliable product information and user support for the FIP treatment field.
NeoFipronis® (Pronidesivir) Oral GS-441524 Tablets Officially Launched
Officially registered in Laos, NeoFipronis® (Pronidesivir) provides a traceable, quality-controlled oral GS-441524 veterinary product option for cats with feline infectious peritonitis.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is the active pharmaceutical ingredient. The product has been officially registered in Laos and is now available through authorized channels, marking an important step toward a more standardized, traceable, and quality-controlled approach to FIP-related treatment management.Feline infectious peritonitis is a serious and life-threatening disease in cats. For many years, FIP was considered one of the most difficult feline diseases to manage. With the development and clinical application of GS-441524, FIP treatment has entered a new stage, giving veterinarians and cat owners more options for managing this challenging disease.NeoFipronis® (Pronidesivir) Oral Tablets are designed for convenient oral administration during FIP treatment. Compared with injectable options, oral tablets may help reduce stress for cats and improve daily administration compliance during longer treatment courses.Each batch of NeoFipronis® (Pronidesivir) is manufactured under controlled quality standards and supported by batch traceability and product verification. This helps veterinarians, distributors, and cat owners identify authentic products and reduce the risks associated with unverified or unauthorized sources.The launch of NeoFipronis® (Pronidesivir) reflects a continued commitment to providing a reliable, traceable, and veterinarian-guided oral GS-441524 product option for cats affected by FIP.FIP diagnosis, dosage planning, treatment duration, and monitoring should be guided by a licensed veterinarian or qualified animal health professional. Treatment decisions should be based on the cat’s clinical condition, body weight, laboratory results, disease type, and professional veterinary judgment.Cat owners and partners are encouraged to purchase products only through authorized channels. Unverified products may carry risks such as inconsistent composition, inaccurate dosage, lack of traceability, or uncertain quality.With the official launch of NeoFipronis® (Pronidesivir), the brand aims to support a more transparent, standardized, and quality-focused approach to FIP-related treatment access.
FIP Symptoms, Diagnosis, and Treatment | Complete Guide to Feline Infectious Peritonitis (FIP) Prevention and Care
IntroductionFeline Infectious Peritonitis (FIP) is one of the most complex and concerning diseases in feline medicine. Caused by a mutated feline coronavirus (FCoV), FIP can progress rapidly and affect multiple organs, leading to severe illness. For years, it was regarded as an incurable condition, but with the introduction of advanced antiviral therapies, effective treatment is now possible. This guide explains FIP symptoms, how the disease is diagnosed, the treatment options available, and essential prevention strategies for cat owners.1. Recognizing Symptoms of FIPSymptoms of FIP vary depending on whether the cat has the effusive (wet) form or the non-effusive (dry) form.Wet (Effusive) FIP: Characterized by fluid buildup in the abdomen or chest. Cats may have swollen bellies, difficulty breathing, persistent fever, lethargy, and weight loss.Dry (Non-Effusive) FIP: More challenging to detect. Symptoms include neurological problems such as seizures, imbalance, or paralysis; eye changes like uveitis or retinal lesions; chronic fever; and gradual weight loss.General Signs: Poor appetite, depression, anemia, and chronic inflammation. Early symptoms may resemble other illnesses, so careful evaluation is essential.2. How FIP Is DiagnosedThere is no single definitive test for FIP. Instead, veterinarians rely on a combination of medical history, physical examination, and laboratory findings.Blood Tests: High globulin levels, low albumin-to-globulin ratio, anemia, and elevated white blood cell counts are common.Fluid Analysis: In effusive FIP, fluid from the chest or abdomen is examined. FIP fluid is typically thick, yellow, and protein-rich.Imaging: Ultrasound or X-rays can detect fluid accumulation, enlarged lymph nodes, or organ involvement.PCR Testing: Detects coronavirus RNA, though a positive result does not always mean FIP.Clinical Evaluation: Veterinarians combine test results with clinical signs to reach a presumptive diagnosis.3. Treatment Options for FIPThe biggest breakthrough in FIP treatment has been the development of antiviral drugs that inhibit viral replication.GS-441524: A nucleoside analog proven highly effective in blocking viral replication. Survival rates in treated cats now exceed 80–90%.Pronidesivir (NeoFipronis®): An oral formulation of GS-441524 specifically designed for veterinary use. Easier to administer and less stressful for cats compared to injections.Remdesivir: Used in some countries as an alternative, since it metabolizes into GS-441524 in the body.Treatment Duration: Typically requires 12 weeks of continuous therapy, with dosages adjusted for weight and disease severity. Neurological or ocular cases require higher dosages.4. Supportive Care During TreatmentAntivirals are the cornerstone, but supportive measures enhance recovery and improve quality of life.Nutritional Support: High-quality, protein-rich diets help maintain body weight and strength.Immune Support: Taurine, omega-3 fatty acids, probiotics, and vitamins support general health.Anti-inflammatory Medications: Used selectively to reduce severe inflammation, though less critical with effective antiviral treatment available.Symptom Management: Intravenous fluids, appetite stimulants, or antibiotics may be used as needed.5. Monitoring and Follow-UpDuring and after treatment, regular veterinary check-ups are essential.Blood Monitoring: CBC and biochemical tests every few weeks to assess response and detect organ stress.Weight Tracking: Weight gain indicates positive response to treatment.Neurological Assessments: In dry FIP cases with neurological involvement, progress must be monitored closely.Post-Treatment Surveillance: Even after completing the full course, periodic checks ensure no relapse occurs.6. Prevention of FIPSince not every coronavirus infection leads to FIP, prevention focuses on reducing viral load and supporting immunity.Hygiene: Keep litter boxes clean and reduce overcrowding in multi-cat households.Stress Reduction: Cats in low-stress environments have stronger immune defenses.Cattery Management: Breeders must avoid high-density housing and monitor breeding lines for FIP history.Wellness Care: Regular veterinary visits and balanced nutrition strengthen resilience against infection.7. The Future of FIP ResearchThe future is optimistic. Ongoing research aims to refine antiviral drugs, develop safe vaccines, and explore combination therapies for more complex cases. With more veterinary-approved products like Pronidesivir becoming available, treatment will become more accessible and standardized.ConclusionFIP has transformed from a fatal disease into a treatable condition thanks to modern antiviral therapy. By recognizing symptoms early, ensuring accurate diagnosis, and committing to full-course treatment, cat owners can provide their pets with a real chance at recovery. Combined with preventive care, these advances bring new hope for cats worldwide.
FIP Treatment Medications Explained | New Advances in Feline Infectious Peritonitis (FIP) Prevention and Therapy
IntroductionFeline Infectious Peritonitis (FIP) is one of the most challenging diseases in feline medicine. For decades, a diagnosis of FIP was almost always fatal, leaving veterinarians and cat owners with no effective therapeutic options. However, with the discovery and application of new antiviral drugs, the landscape has changed dramatically. Today, FIP is no longer an automatic death sentence, and treatment outcomes continue to improve. This article provides a comprehensive overview of the medications used to treat FIP, their mechanisms, clinical effectiveness, and the latest prevention strategies.1. Understanding FIP and Why Treatment Was DifficultFIP is caused by mutations of the feline coronavirus (FCoV). While most cats infected with FCoV show no or mild symptoms, in some cases the virus mutates and gains the ability to replicate within immune cells, spreading throughout the body and causing severe inflammation. This leads to two primary clinical forms: the wet (effusive) form, characterized by fluid accumulation in the abdomen or chest, and the dry (non-effusive) form, which can involve the eyes, nervous system, and various organs. Historically, the difficulty in treating FIP lay in the fact that the virus hides within immune cells, making it extremely hard to target and eliminate. Supportive care such as fluids, anti-inflammatories, and immune boosters could alleviate symptoms temporarily, but none of these therapies addressed the underlying viral replication.2. Antiviral Medications: The BreakthroughThe true revolution in FIP treatment came with the discovery of nucleoside analogs, specifically GS-441524, a compound closely related to Remdesivir. GS-441524 inhibits viral RNA polymerase, effectively blocking viral replication within the cat’s body. This allowed, for the first time, not just symptom management but true disease remission and recovery.GS-441524: The foundational molecule for FIP therapy. Administered orally or via injection, it directly inhibits the replication of FCoV. Clinical studies have shown survival rates exceeding 80–90% in cats treated with GS-441524.Pronidesivir (NeoFipronis®): A veterinary-approved oral formulation of GS-441524. Unlike injectable forms, oral tablets are easier to administer, reduce stress for cats and owners, and are highly effective in long-term therapy.Remdesivir: Approved for human use against COVID-19, it metabolizes into GS-441524 in the body. In some regions, Remdesivir has been used in veterinary practice as an alternative, especially when GS-441524 was not readily available.3. Clinical Effectiveness of Antiviral TreatmentTreatment success depends on several factors, including the form of FIP, the stage at which therapy begins, and the correct dosage.Standard Treatment Protocols: Most cases require at least 12 weeks (84 days) of continuous therapy. Dosing is weight-based, usually around 10–15 mg/kg/day for effusive and non-effusive forms, while neurological and ocular cases may need 20 mg/kg/day or higher.Response to Treatment: Many cats show rapid improvement within days to weeks of starting therapy. Appetite, energy, and body weight increase, fever resolves, and fluid accumulation diminishes.Long-Term Recovery: With a full and properly monitored treatment course, most cats achieve long-term remission. Relapse is possible if the treatment is stopped prematurely or dosing is insufficient.4. Supportive Medications and Adjunct TherapiesWhile antivirals form the cornerstone of treatment, additional medications can play important roles in improving quality of life and overall survival.Anti-inflammatories: Corticosteroids were traditionally used to reduce inflammation, but with effective antivirals available, their role has diminished. They may still be helpful for specific cases of severe inflammation.Immune Modulators: Interferons and other immune-supporting agents have been tried with variable success. They are not curative but can provide supportive benefits.Nutritional Supplements: Taurine, omega-3 fatty acids, vitamin E, and antioxidants support overall health and recovery. Probiotics and gut-protective supplements are also used to reduce secondary infections and gastrointestinal upset.5. Monitoring During TreatmentEffective therapy requires careful monitoring to ensure success and detect complications early.Bloodwork: Regular complete blood counts (CBC) and biochemistry panels are recommended to track anemia, protein levels, and organ function.Body Weight and Appetite: Monitoring weight gain and food intake provides a direct measure of recovery.Neurological and Ocular Signs: In cases with central nervous system or eye involvement, ongoing assessment of symptoms is vital to adjust dosing.6. Challenges and ConsiderationsWhile treatment outcomes are promising, challenges remainCost: Long treatment durations and high daily doses can make therapy expensive.Access to Medication: In some regions, legal access to GS-441524 or veterinary formulations may still be limited.Owner Compliance: Daily medication for 12 weeks requires strong commitment from cat owners, as missed doses can reduce effectiveness.7. Prevention StrategiesSince not all cats exposed to feline coronavirus develop FIP, prevention focuses on reducing overall exposure and maintaining strong immune health.Hygiene in Multi-Cat Households: Clean litter boxes frequently and avoid overcrowding.Reduce Stress: Stress weakens immunity and increases the risk of viral mutation. Provide stable, low-stress environments.Responsible Breeding: Catteries should manage population density carefully and avoid breeding cats with a history of FIP.General Wellness: Proper nutrition, regular veterinary visits, and vaccination against other infectious diseases strengthen overall health and resistance.8. The Future of FIP TreatmentResearch into FIP therapies continues to evolve. Combination treatments, new delivery methods, and improvements in accessibility promise even better outcomes. In addition, efforts to develop effective vaccines are ongoing, although none are yet universally reliable. With continued scientific progress, FIP may soon become not just a treatable but a preventable disease.ConclusionThe story of FIP has shifted from despair to hope. Once considered untreatable, it is now a disease with high survival rates when managed correctly. Antiviral medications such as GS-441524 and Pronidesivir (NeoFipronis®) represent a medical breakthrough, offering cats worldwide a chance at full recovery. Alongside antivirals, supportive therapies, preventive strategies, and responsible cat ownership all contribute to better outcomes. For veterinarians and cat owners alike, knowledge of these treatments and commitment to early diagnosis and full-course therapy are the keys to success.

INDICATION AND IMPORTANT SAFETY INFORMATION

WHAT IS NEOFIPRONIS® (Pronidesivir)?

NeoFipronis® (Pronidesivir) is a non-prescription veterinary medicine used for the treatment of feline infectious peritonitis (FIP) in cats. It is indicated for all known forms of FIP, including effusive (wet), non-effusive (dry), neurological, and ocular types.

The active ingredient in NeoFipronis® is GS‑441524, a nucleoside analog widely known for its potent antiviral activity against feline coronaviruses. Its official International Nonproprietary Name (INN) is Pronidesivir.

NeoFipronis® (Pronidesivir) is not approved for use in humans and should only be administered to cats. Use under the guidance of a licensed veterinarian is strongly recommended.

Do not exceed the recommended daily dosage. Overdosing may increase the risk of adverse effects, including liver or kidney strain.

IMPORTANT SAFETY INFORMATION

Before giving NeoFipronis® (Pronidesivir) to your cat, tell your veterinarian if your cat:

  • Is under 4 weeks of age
  • Is pregnant or suspected to be pregnant
  • Has known liver or kidney disease
  • Is receiving other medications, supplements, or undergoing concurrent treatment

Using NeoFipronis® (Pronidesivir) with other medications may alter its effectiveness or increase the risk of interactions. Always inform your veterinarian of any other treatments your cat is receiving.

The standard dose is 15mg/kg orally once daily on an empty stomach. Higher doses (up to 30mg/kg) may be needed for cats with neurological or ocular FIP. Do not change the dosage without veterinary advice.

What are the possible side effects of NeoFipronis® (Pronidesivir) ?

The most commonly observed side effects include vomiting, loss of appetite, lethargy, and mild gastrointestinal discomfort. These effects are generally manageable and reversible. Serious adverse effects are rare when used as directed.

Regular monitoring of your cat’s bloodwork—including liver and kidney function—is recommended during treatment. Discontinue use and contact your veterinarian immediately if serious reactions occur.

Talk to your veterinarian for medical advice about side effects or concerns regarding treatment.

NeoFipronis® (Pronidesivir) is a non-prescription veterinary medicine, and its use under veterinary supervision is strongly recommended.

Keep out of reach of children and animals. Not for human use.

For full prescribing information and product details, please visit:www.pronidesivir.com.